0000891839-20-000119.txt : 20200518
0000891839-20-000119.hdr.sgml : 20200518
20200518162029
ACCESSION NUMBER: 0000891839-20-000119
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200514
FILED AS OF DATE: 20200518
DATE AS OF CHANGE: 20200518
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Van Strydonck, Gerald E.
CENTRAL INDEX KEY: 0001748247
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38624
FILM NUMBER: 20889783
MAIL ADDRESS:
STREET 1: 1895 MOUNT HOPE AVENUE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VACCINEX, INC.
CENTRAL INDEX KEY: 0001205922
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 161603202
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1895 MOUNT HOPE AVE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
BUSINESS PHONE: 585-271-2700
MAIL ADDRESS:
STREET 1: 1895 MOUNT HOPE AVE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
FORMER COMPANY:
FORMER CONFORMED NAME: VACCINEX INC
DATE OF NAME CHANGE: 20021114
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-05-14
0001205922
VACCINEX, INC.
VCNX
0001748247
Van Strydonck, Gerald E.
C/O VACCINEX, INC.
1895 MOUNT HOPE AVENUE
ROCHESTER
NY
14620
1
0
0
0
Stock Option (Right to Buy)
14.90
2023-03-06
Common Stock
7500
7500
D
Stock Option (Right to Buy)
13.60
2027-09-15
Common Stock
6396
6396
D
Stock Option (Right to Buy)
5.26
2029-03-30
Common Stock
2501
2501
D
Stock Option (Right to Buy)
7.78
2020-05-15
Common Stock
7718
7718
D
Stock Option (Right to Buy)
5.52
2019-06-30
2029-06-29
Common Stock
2385
2385
D
Stock Option (Right to Buy)
7.17
2019-09-30
2029-09-27
Common Stock
1856
1856
D
Stock Option (Right to Buy)
4.85
2019-12-31
2029-12-28
Common Stock
2737
2737
D
Stock Option (Right to Buy)
3.95
2020-05-14
4
A
0
15679
0
A
2021-05-14
Common Stock
15679
15679
D
Exercisable in full as of the date of this report.
This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
/s/ Scott E. Royer, Attorney-in-Fact for Gerald E. Van Strydonck
2020-05-18